DALLAS, May 22, 2017 (GLOBE NEWSWIRE) -- Arog Pharmaceuticals, Inc., a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, today announced that it will feature two clinical poster presentations on the company’s lead product candidate, crenolanib, at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2017 in Chicago. Crenolanib continues to demonstrate best-in-class properties in the treatment of acute myeloid leukemia (AML) with FLT3 mutations.

Poster Discussion and Presentation, Abstract #7016

Title: Effect of cytarabine/anthracycline/crenolanib induction on minimal residual disease (MRD) in newly diagnosed FLT3 mutant AML

Authors: Richard M. Stone, Robert Collins, Martin S. Tallman, Roland B. Walter, Chatchada Karanes, Prapti A. Patel, Madhuri Vusirikala, Catherine C. Coombs, Gretchen Olson, Vinay K. Jain, Eunice S. Wang

Poster Presentation Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Date: Monday, June 5, 2017
Time: 8:00 – 11:30 AM CST
Location: Hall A
Poster Board: 216

Poster Discussion Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Date: Monday, June 5, 2017
Time: 11:30 – 12:45 PM CST
Location: E354b

Poster Presentation, Abstract # TPS11080

Title: A randomized, double-blind, placebo-controlled, phase III study of crenolanib in advanced or metastatic GIST patients bearing a D842V mutation in PDGFRA: the CrenoGIST study

Authors: Jean-Yves Blay, Michael C. Heinrich, Peter Hohenberger, Paolo Giovanni Casali, Piotr Rutkowski, Cesar Serrano-Garcia, Robin Lewis Jones, Kirsten Sundby Hall, John Randall Eckardt, Margaret von Mehren

Poster Session: Sarcoma
Date: Sunday, June 4, 2017
Time: 8:00 – 11:30 AM CST
Location: Hall A
Poster Board: 402b

About Arog Pharmaceuticals, Inc.

Arog Pharmaceuticals is a private, clinical-stage biopharmaceutical company that has leveraged its platform of benzimidazole derivatives to develop a robust drug pipeline of orally available, potent, and selective small molecule type I tyrosine kinase inhibitors (TKIs).  Arog is undergoing pivotal, randomized Phase III trials of its lead molecule, crenolanib.  For more information, please visit the company’s website, http://www.arogpharma.com.

About Crenolanib 

Arog’s lead molecule, crenolanib, is a type I TKI that selectively and potently inhibits signaling of wild-type and mutant isoforms of class III receptor tyrosine kinases (RTKs), FLT3 and PDGFRα/β.  Crenolanib has an established record of patient safety and has been used to treat over 350 patients. Crenolanib is currently being clinically investigated in combination with standard induction or salvage chemotherapy in patients with FLT3 mutant acute myeloid leukemia (AML). Additionally, crenolanib is being clinically investigated in solid tumors, including gastrointestinal stromal tumors (GIST) harboring the PDGFRα D842V mutation.

About FLT3 

FLT3 is a class III RTK, and its signaling is considered important for the normal development of hematopoietic stem cells and progenitor cells.  The FLT3 gene is one of the most frequently mutated genes (~30%) in AML.  One such mutation, internal tandem duplications of FLT3 (FLT3-ITD), is a prognostic indicator associated with adverse disease outcome.

About PDGFRα D842V Mutations  

PDGFRAD842V is a gain-of-function mutation that constitutively activates PDGFRA downstream signaling pathway. D842V is the most common PDGFRA mutation and is well-known to be resistant to imatinib and sunitinib.   

Contact:

The Trout Group
Peter Rahmer
(646) 378-2973
prahmer@troutgroup.com